CN103585209B - 阿莫尼亚脂提取物在制备抗肝癌药物中的应用 - Google Patents
阿莫尼亚脂提取物在制备抗肝癌药物中的应用 Download PDFInfo
- Publication number
- CN103585209B CN103585209B CN201310525381.0A CN201310525381A CN103585209B CN 103585209 B CN103585209 B CN 103585209B CN 201310525381 A CN201310525381 A CN 201310525381A CN 103585209 B CN103585209 B CN 103585209B
- Authority
- CN
- China
- Prior art keywords
- dorema ammoniacum
- ammoniacum resin
- resin extract
- extract
- dorema
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000011347 resin Substances 0.000 title claims abstract description 175
- 229920005989 resin Polymers 0.000 title claims abstract description 175
- 241001096899 Ferula ammoniacum Species 0.000 title claims abstract description 159
- 239000000284 extract Substances 0.000 title claims abstract description 131
- 239000003814 drug Substances 0.000 title claims abstract description 33
- 229940079593 drug Drugs 0.000 title claims abstract description 24
- 201000007270 liver cancer Diseases 0.000 title claims abstract description 23
- 208000014018 liver neoplasm Diseases 0.000 title claims abstract description 23
- 239000000341 volatile oil Substances 0.000 claims abstract description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 67
- 238000000605 extraction Methods 0.000 claims description 48
- PFRGXCVKLLPLIP-UHFFFAOYSA-N diallyl disulfide Chemical compound C=CCSSCC=C PFRGXCVKLLPLIP-UHFFFAOYSA-N 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 238000002360 preparation method Methods 0.000 claims description 16
- 239000002904 solvent Substances 0.000 claims description 16
- 238000002156 mixing Methods 0.000 claims description 12
- FCWYNTDTQPCVPG-UHFFFAOYSA-N Marmaricin Natural products C1=CC(=O)OC2=CC(OCC3C4(C)CCC(O)C(C4CCC3=C)(C)C)=CC=C21 FCWYNTDTQPCVPG-UHFFFAOYSA-N 0.000 claims description 10
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims description 9
- 239000008187 granular material Substances 0.000 claims description 9
- 238000010438 heat treatment Methods 0.000 claims description 9
- 230000000274 adsorptive effect Effects 0.000 claims description 8
- 230000001476 alcoholic effect Effects 0.000 claims description 8
- 239000006286 aqueous extract Substances 0.000 claims description 8
- 239000012141 concentrate Substances 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 8
- 239000003480 eluent Substances 0.000 claims description 8
- 238000010992 reflux Methods 0.000 claims description 8
- 238000001256 steam distillation Methods 0.000 claims description 8
- 239000003463 adsorbent Substances 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- WNANPKYNOALKIV-XJRISUEFSA-N 7-[[(1r,2s,4as,6s,8ar)-2,6-dihydroxy-2,5,5,8a-tetramethyl-3,4,4a,6,7,8-hexahydro-1h-naphthalen-1-yl]methoxy]chromen-2-one Chemical compound C1=CC(=O)OC2=CC(OC[C@H]3[C@]4(C)CC[C@H](O)C(C)(C)[C@H]4CC[C@@]3(O)C)=CC=C21 WNANPKYNOALKIV-XJRISUEFSA-N 0.000 claims description 5
- FCWYNTDTQPCVPG-SMVUYSJCSA-N 7-[[(4as)-6-hydroxy-5,5,8a-trimethyl-2-methylidene-3,4,4a,6,7,8-hexahydro-1h-naphthalen-1-yl]methoxy]chromen-2-one Chemical compound C1=CC(=O)OC2=CC(OCC3C4(C)CCC(O)C([C@H]4CCC3=C)(C)C)=CC=C21 FCWYNTDTQPCVPG-SMVUYSJCSA-N 0.000 claims description 5
- HRDQCXAGCMJUDE-UHFFFAOYSA-N Badrakemin Natural products CC1(C)C(O)CCC2(C)C1CCC(COc3ccc4C=CC(=O)Oc4c3)C2=C HRDQCXAGCMJUDE-UHFFFAOYSA-N 0.000 claims description 5
- WNANPKYNOALKIV-UHFFFAOYSA-N Isosamarcandin+ Natural products C1=CC(=O)OC2=CC(OCC3C4(C)CCC(O)C(C)(C)C4CCC3(O)C)=CC=C21 WNANPKYNOALKIV-UHFFFAOYSA-N 0.000 claims description 5
- MNGYOFNIAOWXIT-UHFFFAOYSA-N Polyanthinin Natural products C1=CC(=O)OC2=CC(OCC3C4(C)CCC(C(C4CCC3=C)(C)C)OC(=O)C)=CC=C21 MNGYOFNIAOWXIT-UHFFFAOYSA-N 0.000 claims description 5
- PJXNPYBRJFKRPB-UHFFFAOYSA-N mogoltadone Natural products C1=CC(=O)OC2=CC(OCC3C(=C)CCC4C(C(CCC43C)=O)(C)C)=CC=C21 PJXNPYBRJFKRPB-UHFFFAOYSA-N 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 2
- 238000000746 purification Methods 0.000 abstract description 5
- 238000005516 engineering process Methods 0.000 abstract description 4
- 239000002994 raw material Substances 0.000 abstract description 2
- 239000000203 mixture Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 25
- 206010028980 Neoplasm Diseases 0.000 description 18
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 description 9
- 239000003208 petroleum Substances 0.000 description 9
- 201000011510 cancer Diseases 0.000 description 8
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 239000002574 poison Substances 0.000 description 5
- 229960001674 tegafur Drugs 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 231100000614 poison Toxicity 0.000 description 4
- 208000037920 primary disease Diseases 0.000 description 4
- 241000125183 Crithmum maritimum Species 0.000 description 3
- 241001232378 Grindelia Species 0.000 description 3
- 235000005717 Grindelia squarrosa Nutrition 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 238000012790 confirmation Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000001819 mass spectrum Methods 0.000 description 3
- 238000002953 preparative HPLC Methods 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- -1 and dry Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000001644 anti-hepatocarcinoma Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000008451 emotion Effects 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 238000011532 immunohistochemical staining Methods 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229930195730 Aflatoxin Natural products 0.000 description 1
- XWIYFDMXXLINPU-UHFFFAOYSA-N Aflatoxin G Chemical compound O=C1OCCC2=C1C(=O)OC1=C2C(OC)=CC2=C1C1C=COC1O2 XWIYFDMXXLINPU-UHFFFAOYSA-N 0.000 description 1
- 208000008822 Ankylosis Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000202726 Bupleurum Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 206010073069 Hepatic cancer Diseases 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 108010042653 IgA receptor Proteins 0.000 description 1
- 206010061245 Internal injury Diseases 0.000 description 1
- 206010023198 Joint ankylosis Diseases 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 102100034014 Prolyl 3-hydroxylase 3 Human genes 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 108700025695 Suppressor Genes Proteins 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000005409 aflatoxin Substances 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000005202 decontamination Methods 0.000 description 1
- 230000003588 decontaminative effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 239000009519 fu-yuan Substances 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000012151 immunohistochemical method Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 201000007450 intrahepatic cholangiocarcinoma Diseases 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310525381.0A CN103585209B (zh) | 2013-10-31 | 2013-10-31 | 阿莫尼亚脂提取物在制备抗肝癌药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310525381.0A CN103585209B (zh) | 2013-10-31 | 2013-10-31 | 阿莫尼亚脂提取物在制备抗肝癌药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103585209A CN103585209A (zh) | 2014-02-19 |
CN103585209B true CN103585209B (zh) | 2015-09-23 |
Family
ID=50075663
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310525381.0A Expired - Fee Related CN103585209B (zh) | 2013-10-31 | 2013-10-31 | 阿莫尼亚脂提取物在制备抗肝癌药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103585209B (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105287962A (zh) * | 2015-11-20 | 2016-02-03 | 杨美娟 | 一种中药组合提取物及其在制备胃癌药物中的应用 |
CN105997641A (zh) * | 2016-06-14 | 2016-10-12 | 孙跃 | 一种植物提取型化妆水 |
EP3784230B1 (en) * | 2018-04-26 | 2022-11-30 | T.C. Istanbul Medipol Universitesi | The use of terpenic coumarine derivative molecules in the treatment of cancer disease |
WO2020055368A2 (en) * | 2018-09-12 | 2020-03-19 | Istanbul Medipol Universitesi | Usage of terpenic coumarin derived molecules in treating viral diseases |
CN112569214A (zh) * | 2019-09-29 | 2021-03-30 | 山东大学 | 二烯丙基硫醚在制备预防和/或治疗肝纤维化及肝癌药物中的应用 |
-
2013
- 2013-10-31 CN CN201310525381.0A patent/CN103585209B/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN103585209A (zh) | 2014-02-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103585209B (zh) | 阿莫尼亚脂提取物在制备抗肝癌药物中的应用 | |
Li et al. | Induction of apoptosis by berberine in hepatocellular carcinoma HepG2 cells via downregulation of NF-κB | |
CN101590134B (zh) | 具有抗炎镇痛作用的地榆总三萜及其制备方法 | |
CN101310751B (zh) | 一种具有益气养血作用的药物组合物的检测方法 | |
CN107868068B (zh) | 一类乌药烷型二聚倍半萜类化合物、其制备方法及用途 | |
CN106236801A (zh) | 超微破壁粉碎技术制成的三七活性药物及保健品及其制法 | |
Li et al. | Ginsenoside Rb1 protects dopaminergic neurons from inflammatory injury induced by intranigral lipopolysaccharide injection | |
CN104189099A (zh) | 肉苁蓉苯乙醇苷提取物在防治高原病中的应用 | |
Gong et al. | Synergistic nourishing ‘Yin’effect of iridoid and phenylpropanoid glycosides from Radix Scrophulariae in vivo and in vitro | |
CN103405487B (zh) | 一种具有治疗关节炎作用的中药复方有效部位 | |
CN101829214B (zh) | 金樱叶提取物及其在制备治疗烧烫伤药物中的应用 | |
CN104800236B (zh) | 具有镇咳活性的细辛总多糖提取物及其提取方法和应用 | |
Liang et al. | Effect of Chinese herbal compound on liver fibrosis in rabbits with schistosomiasis by B-ultrasound | |
CN103721148B (zh) | 一种治疗急慢性胃肠炎的益智仁组合物及其制备方法 | |
CN102283910B (zh) | 抗抑郁作用的中药组合物及其制剂和制备方法 | |
CN103585190B (zh) | 壁衣提取物在制备抗肝癌药物中的应用 | |
CN100444849C (zh) | 刺蒺藜提取物的新用途 | |
CN102018747B (zh) | 红芪和红芪多糖在制备改善学习记忆及治疗阿尔茨海默病药物的应用 | |
CN101904894B (zh) | 独一味总苷在制备药物中的用途 | |
CN103211833A (zh) | 淫羊藿苷在制备治疗痛风药物中的应用 | |
CN104473936A (zh) | 一种治疗肝癌的药物组合物 | |
CN104510749A (zh) | 一种治疗肝癌的药物组合物 | |
CN104473949A (zh) | 一种治疗肝癌的药物组合物 | |
CN104523726A (zh) | 一种治疗肝癌的药物组合物 | |
CN101816702B (zh) | 取自夏枯草的防治肺癌组合物及其在制备防治肺癌药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: AFFILIATED HOSPITAL OF QINGDAO UNIVERSITY Free format text: FORMER OWNER: JINAN XINGYI MEDICAL TECHNOLOGY CO., LTD. Effective date: 20150824 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C53 | Correction of patent for invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Chen Qingfeng Inventor after: Xu Hefei Inventor after: Wang Zhengkun Inventor after: Wang Haibo Inventor after: Li Funian Inventor before: Kong Qianqian |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: KONG QIANQIAN TO: CHEN QINGFENG XU HEFEI WANG ZHENGKUN WANG HAIBO LI FUNIAN |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20150824 Address after: 266003 Jiangsu Road, Shandong, China, No. 16, No. Applicant after: Affiliated Hospital of University Of Qingdao Address before: 250101 No. 51 Industrial South Road, Ji'nan hi tech Zone, Shandong, Ji'nan Applicant before: Jinan Xingyi Medical Technology Co.,Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150923 Termination date: 20161031 |
|
CF01 | Termination of patent right due to non-payment of annual fee |